|1.||Haass, Christian: 47 articles (07/2013 - 06/2002)|
|2.||Wolfe, Michael S: 37 articles (10/2015 - 04/2002)|
|3.||De Strooper, Bart: 36 articles (11/2015 - 04/2004)|
|4.||Steiner, Harald: 36 articles (03/2015 - 06/2002)|
|5.||Tomita, Taisuke: 31 articles (02/2015 - 04/2002)|
|6.||Iwatsubo, Takeshi: 28 articles (02/2015 - 04/2002)|
|7.||Li, Yue-Ming: 27 articles (08/2015 - 02/2002)|
|8.||Vassar, Robert: 25 articles (01/2015 - 12/2002)|
|9.||Golde, Todd E: 22 articles (01/2015 - 03/2002)|
|10.||Winblad, Bengt: 20 articles (09/2015 - 07/2003)|
|1.||Alzheimer Disease (Alzheimer's Disease)
08/01/2000 - "The latter is an important finding from the perspective of therapeutic treatment of Alzheimer's disease by targeting gamma-secretase processing of APP to reduce Abeta production."
12/18/2013 - "The antibody is probably therefore acting by steric hindrance of β-secretase and these data suggest that it will be effective in mice in vivo and could be an alternative potential therapy for Alzheimer's disease. "
02/01/2005 - "gamma-Secretase inhibitors are one promising approach to the development of a therapeutic for Alzheimer's disease (AD). "
01/01/2008 - "Gamma-secretase modulation holds the promise for the development of a disease-modifying therapy for Alzheimer's disease (AD). "
01/01/2008 - "Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective."
05/01/2011 - "These findings might have direct translational implications because different inhibitors of the γ-secretase complex are available and have yielded promising results in cancer trials."
08/01/2015 - "According to recent studies, γ-secretase inhibitors (GSIs), which function as Notch signaling inhibitors, could be used as therapeutic drugs in cancer. "
01/01/2013 - "In this study, we investigated the effects of Notch inhibition by γ-secretase inhibitor IX (GSI IX) in cultured human CC cell lines and we established a transgenic mouse model with liver specific expression of the intracellular domain of Notch (Notch-ICD) and inactivation of tumor suppressor p53. "
07/01/2012 - "Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors."
09/01/2007 - "In this study, we show that NOTCH signaling, as measured by the gamma-secretase cleavage product N(IC)-1, is active in both normal human and lung tumor samples; however, downstream NOTCH readouts (i.e., HES-1 and HES-5) are elevated in lung tumors. "
12/01/2010 - "Interestingly, we observed a moderate, but significant, reduction in amyloid deposits in the forebrain of mice expressing S-palmitoylation-deficient γ-secretase subunits compared with mice overexpressing wild-type subunits, as well as a reduction in the levels of insoluble Aβ(40-42). "
03/21/2008 - "After inhibitor treatment, the improved memory function was accompanied by reduced amyloid plaque load, decreased Abeta40 and Abeta42, and reduced C-terminal beta-secretase fragment derived from APP by beta-secretase. "
12/01/2015 - "Additionally, we show that the impact that SEL-12 has on mitochondrial function is independent of its role in Notch signaling, γ-secretase proteolytic activity, and amyloid plaques. "
08/01/2014 - "Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures."
09/01/2013 - "The Alzheimer's β-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques."
02/01/2014 - "Finally, mice treated with inhibitors of γ-secretase and HIF-1α exhibited improved outcome after focal ischemic stroke, with combined treatment being superior to individual treatments. "
07/01/2011 - "Treatment of mice with a γ-secretase inhibitor, compound E, reduced infarct size and improved functional outcome in a model of focal ischemic stroke. "
06/01/2006 - "Mice transgenic for antisense Notch and normal mice treated with inhibitors of the Notch-activating enzyme gamma-secretase showed reduced damage to brain cells and improved functional outcome in a model of focal ischemic stroke. "
10/24/2014 - "These results provide further support for the potential use of γ-secretase inhibitors as therapy for ischemic stroke. "
10/24/2014 - "However, the role of γ-secretase-mediated Notch signaling in activating MAPK following ischemic stroke has not been investigated. "
04/01/2011 - "These data establish a functional role for 5-LO in the pathogenesis of AD-like amyloidosis, whereby it modulates the γ-secretase pathway. "
04/01/2008 - "These data establish for the first time a novel functional role for 5LO in the pathogenesis of AD-like amyloidosis, thereby modulating gamma-secretase activity. "
10/03/2007 - "Importantly, we demonstrate that there exists a critical gamma-secretase level that reduces the risk of amyloidosis in the CNS and limits tumorigenesis in epithelia. "
01/06/2010 - "Because the processing of APP to generate Abeta requires both gamma-secretase and BACE1, it is possible that moderate reductions of both enzymes would provide additive and significant protection against Abeta amyloidosis. "
11/15/2010 - "In vivo and in vitro studies show that the effect of this enzymatic pathway on amyloidosis is mediated by modulation of Aβ precursor protein processing via the β secretase (BACE) proteolytic cascade, which ultimately results in altered formation of Aβ peptides. "
|1.||Amyloid (Amyloid Fibrils)
|3.||Proteins (Proteins, Gene)
|4.||Folic Acid (Vitamin M)
|5.||2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))
|6.||2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamide
|8.||N2- ((2S)- 2- (3,5- difluorophenyl)- 2- hydroxyethanoyl)- N1- ((7S)- 5- methyl- 6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- L- alaninamide
|9.||2- (5,7- difluoro- 1,2,3,4- tetrahydronaphthalen- 3- ylamino)- N- (1- (2- methyl- 1- (neopentylamino)propan- 2- yl)- 1H- imidazol- 4- yl)pentanamide
|1.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)